1038915-92-2

Basic information

• Product Name: tert-butyl 3-(4-(7-carbamoyl-2H-indazol-2-yl)phenyl)piperidine-1-carboxylate
• Synonyms: tert-butyl 3-(4-(7-carbamoyl-2H-indazol-2-yl)phenyl)piperidine-1-carboxylate
• CAS NO: 1038915-92-2
• Molecular Weight: 420.511
• Mol File: 1038915-92-2.mol

Chemical Properties

• CAS DataBase Reference: tert-butyl 3-(4-(7-carbamoyl-2H-indazol-2-yl)phenyl)piperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 3-(4-(7-carbamoyl-2H-indazol-2-yl)phenyl)piperidine-1-carboxylate(1038915-92-2)
• EPA Substance Registry System: tert-butyl 3-(4-(7-carbamoyl-2H-indazol-2-yl)phenyl)piperidine-1-carboxylate(1038915-92-2)

Safety Data

• Hazardous Substances Data: 1038915-92-2(Hazardous Substances Data)

Upstream product

• 132874-06-7 methyl 3-(bromomethyl)-2-nitrobenzoate 
• 875798-79-1 3-(4-aminophenyl)piperidine-1-carboxylic acid tert-butyl ester 
• 750585-94-5 2-bromo-3-formyl-benzoic acid methyl ester 
• 1056971-32-4 tert-butyl-3-phenylpiperidine-1-carboxylate 
• 134-20-3 2-carbomethoxyaniline 
• 1038915-90-0 methyl 2-{4-[1-(tert-butoxycarbonyl)piperidin-3-yl]phenyl}-2H-indazole-7-carboxylate 
• 77287-34-4 formamide 
• 138229-59-1 3-formyl-2-nitrobenzoic acid methyl ester 
• 5471-82-9 methyl 3-methyl-2-nitrobenzoate 
• 5437-38-7 3-methyl-2-nitrobenzoic acid 
• 1038915-99-9 tert-butyl 3-[4-({[3-(methoxycarbonyl)-2-nitrophenyl]methylene}amino)phenyl]piperidine-1-carboxylate 

Downstream Products

• 1038915-56-8 racemic 3-{4-[7-(aminocarbonyl)-2H-indazol-2-yl]phenyl}piperidinium chloride 
• 1038915-60-4 (3S)-3-[4-{7-(aminocarbonyl)-2H-indazol-2-yl}phenyl]piperidine 
• 1038915-58-0 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide 

Relevant articles and documents

Indazole formamide compound as well as preparation method and application thereof

The invention belongs to the field of chemical medicines, and particularly relates to an indazole formamide compound as well as a preparation method and application thereof. The invention provides anindazole carboxamide compound or a pharmaceutically acce

Synthesis method for niraparib

The invention discloses a synthesis method for niraparib. The synthesis method comprises the following steps: (1) continuously synthesizing an intermediate A from a compound a, a compound b and tetrabutylammonium azide in a micro-channel reactor; (2) enabling the intermediate A to generate methyl ester ammonolysis reaction to obtain an intermediate B; and (3) enabling the intermediate B to removeBOC, thereby obtaining niraparib. The synthesis method is reasonable in process route design, is short in reaction step, adopts cheap and easily available raw materials, is simple and convenient to operate, is safe and high-efficient, is easily controllable in reaction condition, is high in product yield, is high in purity, and is suitable for industrial production. (The formulae are shown in thespecification.).

Synthesis method for preparing PARP inhibitor Niraparib

The invention provides a novel synthesis method for preparing a PARP inhibitor Niraparib. The method comprises the steps that a starting material methyl anthranilate is subjected to diazo coupling, cyclization, amidation, BOC removal and chiral resolution, and then the Niraparib with the purity reaching 99.5% is obtained. The method is simple, convenient and easy to operate suitable for industrial production.

Synthesis method of novel oral anticancer medicine Nirapairb

The invention discloses a synthesis method of a novel oral anticancer medicine Nirapairb, the method comprises the following steps of subjecting a starting raw material 3-methyl-2-methyl bromobenzoate to a series of reactions of oxidization, aldimine condensation, cyclization, amidation, BOC (tert-Butyloxycarbonyl) removal, chiral separation and the like to obtain optically pure Niraparib of which the purity reaches 98.2 percent. The method is simple to operate, and is applicable to industrialized production; synthesis steps are few; a reaction condition is easily controlled.

Niraparib synthesis method

The invention discloses a Niraparib synthesis method. The method comprises that through esterification, 3-methyl hydroformylation, 3-schiff base reaction, cyclization, amidation, BOC removal and chiral resolution, optically pure Niraparib with purity of 91% or more is prepared from 3-methyl-2-nitrobenzoic acid. The method has the advantages of simple process, high efficiency, easy operation and less equipment requirement, and is a method suitable for industrial production.

Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors

We disclose the development of a novel series of 2-phenyl-2H-indazole-7- carboxamides as poly(ADP-ribose) polymerase (PARP) 1 and 2 inhibitors. This series was optimized to improve enzyme and cellular activity, and the resulting PARP inhibitors display antiproliferation activities against BRCA-1 and BRCA-2 deficient cancer cells, with high selectivity over BRCA proficient cells. Extrahepatic oxidation by CYP450 1A1 and 1A2 was identified as a metabolic concern, and strategies to improve pharmacokinetic properties are reported. These efforts culminated in the identification of 2-{4-[(3S)-piperidin-3-yl] phenyl}-2H-indazole-7-carboxamide 56 (MK-4827), which displays good pharmacokinetic properties and is currently in phase I clinical trials. This compound displays excellent PARP 1 and 2 inhibition with IC50 = 3.8 and 2.1 nM, respectively, and in a whole cell assay, it inhibited PARP activity with EC50 = 4 nM and inhibited proliferation of cancer cells with mutant BRCA-1 and BRCA-2 with CC50 in the 10-100 nM range. Compound 56 was well tolerated in vivo and demonstrated efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer.

PHARMACEUTICALLY ACCEPTABLE SALTS OF 2-{4-[(3S)-PIPERIDIN-3- YL]PHENYL} -2H-INDAZOLE-7-CARBOXAMIDE

The present invention relates to pharmaceutically acceptable salts of an amide substituted indazole which are inhibitors of the enzyme poly(ADP-ribose)polymerase (PARP), previously known as poly(ADP-ribose)synthase and poly(ADP-ribosyl)transferase. The compounds of the present invention are useful as mono-therapies in tumors with specific defects in DNA-repair pathways and as enhancers of certain DNA -damaging agents such as anticancer agents and radiotherapy. Further, the compounds of the present invention are useful for reducing cell necrosis (in stroke and myocardial infarction), down regulating inflammation and tissue injury, treating retroviral infections and protecting against the toxicity of chemotherapy.